source
- Vir Biotechnology appoints David Liu as chief medical officer to steer hepatitis D phase 3 and cancer programsVir Biotechnology announced the appointment of David Liu, M.D., Ph.D., as its new chief medical officer. Liu comes from a recent stint as CMO at Nuvation Bio and has held senior roles at AstraZene…
- Recon: FDA identifies four deaths in Newron schizophrenia drug trials; Dutch court blocks subcutaneous Keytruda in eight Europea...Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 13d ago↗ source
- Cerevance's solengepras cuts OFF time in phase 3 Parkinson's trial